75999-59-6

Usage

InChI:InChI=1/C13H10F3NO3/c1-2-20-12(19)9-10(18)7-5-3-4-6-8(7)17-11(9)13(14,15)16/h3-6H,2H2,1H3,(H,17,18)

Upstream product

• 75999-60-9 4-hydroxy-2-trifluoromethylquinoline-3-carboxylic acid 
• 64-17-5 ethanol 
• 79424-03-6 ethyl 4,4,4-trifluoro-2-butynate 
• 91-56-5 indole-2,3-dione 
• 75999-58-5 Ethyl (1-phenylamino-2,2,2-trifluoroethylidene)propanedioate 
• 552-89-6 2-nitro-benzaldehyde 
• 685-69-8 ethyl 3-oxo-2,4,4,4-tetrafluoro-butyrate 
• 16714-25-3 2-azidobenzaldehyde 
• 1236060-41-5 2-(2,2,2-trifluoro-1-phenyliminoethyl)malonic acid diethyl ester 
• 62-53-3 aniline 
• 61881-19-4 2,2,2-trifluoro-N-phenyl-acetimidoyl chloride 
• 105-53-3 diethyl malonate 

Downstream Products

• 75999-60-9 4-hydroxy-2-trifluoromethylquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Facile synthesis of fluoroalkylated quinolones using fluoroalk-2-ynoates as fluorinated building blocks

In the presence of Na2CO3, a variety of fluoroalkylated quinolones were efficiently synthesized from isatins and fluoroalk-2-ynoates in good to excellent yields at room temperature. The reaction can proceed via two different ways with Michael adduct or isatoic anhydride as the key intermediate.

Cascade Knoevenagel and aza-Wittig reactions for the synthesis of substituted quinolines and quinolin-4-ols

A [4 + 2] annulation involving cascade Knoevenagel, aza-Wittig and dehydrofluorination reactions is developed for the synthesis of substituted quinolin-4-ols including analogs bearing CF2H, CF3, and C2F5 groups. This simple and highly efficient method is also applicable for the synthesis of substituted quinolines. A number of reported biologically active compounds can be readily prepared by this one-pot synthesis. Green chemistry metrics analysis of the new reaction processes provided favorable results.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Palladium-catalyzed chloroimination of imidoyl chlorides to a triple bond: An intramolecular reaction leading to 4-chloroquinolines

(Chemical Equation Presented) In this paper, a new type of effective chloroimination was reported. This reaction afforded 4-chloro-2-perfluoroalkyl quinolines from fluorinated imidoyl chlorides in high yields. This is the first achievement of oxidative addition-reductive elimination type C-Cl bond activation by chloropalladation.

2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them

Novel 3-quinoline carboxamides of the formula STR1 wherein X' is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, straight or branched alkyl and alkoxy of 1 to 5 carbon atoms, --CF3, --SCF3 and --OCF3, R1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R2 ' is selected from the group consisting of thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidyl and tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of alkyl and alkoxy of 1 to 4 carbon atoms, --CF3, --NO2 and halogen and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic and anti-inflammatory activity and novel intermediates and process for their preparation.